EUVIMEDEUVIMED entdecken
Crossref

Real-world outcomes of biosimilar bevacizumab-bvzr versus reference agent in the management of patients with IDH wild-type glioblastoma

Sanghee Lim, Sara L Maloney, Ugur T Sener, Samantha J Caron, Sani H Kizilbash, Jian L Campian, Bryan J Neth, Ivan D Carabenciov, Joon Uhm, Michael W Ruff

Neuro-Oncology Practice · 12.11.2026

DOI: 10.1093/nop/npag115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 12.11.2026. Verfasst von Sanghee Lim und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Bevacizumab, an anti-VEGF monoclonal antibody, has become a mainstay in the management of malignant gliomas. Multiple bevacizumab biosimilars have been approved since initial FDA approval of the reference agent and have seen widespread use, in part due to reduced costs. However, real-world data evaluating comparability between reference and biosimilar agents, especially for the management of glioblastoma, remain limited. METHODS We performed a retrospective analysis of patients treated with reference bevacizumab (Avastin ®) versus those receiving bevacizumab-bvzr (Zirabev ®), a widely used biosimilar agent for the management of IDH wild-type glioblastoma at our institution between 2019 and 2022. Outcomes of interest included rates of dose-limiting adverse effects associated with anti-angiogenic therapy, as well as survival as measured by overall survival (OS). RESULTS A total of 129 patients were included in our final analysis; 71 received reference drug (bevacizumab) while 58 received the biosimilar agent (bevacizumab-bvzr). Rates of dose-limiting adverse effects were similar between both groups (OR 1.2013, p = 0.7418). On analysis of the entire cohort, concomitant treatment with anticoagulation (OR 3.3045, p = 0.0238) was associated with a higher risk of dose-limiting adverse effects On survival analysis, we found that OS was similar between the bevacizumab (median OS 714 daysdays) and biosimilar (median OS 631 days) groups by both univariate (p = 0.5639). and multivariate (HR 1.0869, p = 0.6916) analyses. CONCLUSIONS Bevacizumab-bvzr demonstrated similar clinical efficacy and safety profile compared to reference bevacizumab in our institutional cohort of IDH-WT glioblastoma patients.

Zitieren

APA

Lim, S., Maloney, S. L., Sener, U. T., Caron, S. J., Kizilbash, S. H., Campian, J. L., Neth, B. J., Carabenciov, I. D., Uhm, J., & Ruff, M. W. (2026). Real-world outcomes of biosimilar bevacizumab-bvzr versus reference agent in the management of patients with IDH wild-type glioblastoma. Neuro-Oncology Practice. https://doi.org/10.1093/nop/npag115

Vancouver

Lim S, Maloney SL, Sener UT, Caron SJ, Kizilbash SH, Campian JL, et al. Real-world outcomes of biosimilar bevacizumab-bvzr versus reference agent in the management of patients with IDH wild-type glioblastoma. Neuro-Oncology Practice. 2026. doi:10.1093/nop/npag115

BibTeX
@article{Lim2026,
  author = {Lim, Sanghee and Maloney, Sara L and Sener, Ugur T and Caron, Samantha J and Kizilbash, Sani H and Campian, Jian L and Neth, Bryan J and Carabenciov, Ivan D and Uhm, Joon and Ruff, Michael W},
  title = {Real-world outcomes of biosimilar bevacizumab-bvzr versus reference agent in the management of patients with IDH wild-type glioblastoma},
  journal = {Neuro-Oncology Practice},
  year = {2026},
  doi = {10.1093/nop/npag115}
}
Kostenlos starten →